HOME >> BIOLOGY >> NEWS
FDA approves Raptiva (efalizumab) for chronic moderate-to-severe plaque psoriasis

South San Francisco, CA, and Berkeley, CA Genentech, Inc. (NYSE: DNA) and XOMA Ltd. (Nasdaq: XOMA) announced today that RAPTIVA (efalizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic moderate-to-severe plaque psoriasis in adults age 18 or older who are candidates for systemic therapy or phototherapy. RAPTIVA is the first biologic therapy that is designed to provide continuous control of chronic moderate-to-severe plaque psoriasis and can be self-administered by patients as a single, once-weekly, subcutaneous injection.

"Today's FDA approval of RAPTIVA underscores our commitment to delivering innovative therapies to patients with unmet medical needs," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. "Through our collaboration with XOMA, the clinical trial investigators and most importantly, the over 2,700 patients who participated in our clinical trials, we are proud to offer a new therapeutic option to help patients manage this chronic disease."

"RAPTIVA represents XOMA's first product approval and is the culmination of a highly successful collaboration with Genentech," said John L. Castello, XOMA's chairman, president and chief executive officer. "The companies have worked together on a robust clinical program that has demonstrated the safety and efficacy of RAPTIVA. We view RAPTIVA now being available to
patients as a worthy testament to the confidence of our shareholders and the hard work and support of both companies'
employees."

"I've been treating psoriasis for over 15 years and have always been frustrated by the limited options available to treat patients with this chronic disease. Safety limitations of traditional therapies have made it difficult to offer patients continuous relief," said Craig Leonardi, M.D., clinical associate professor of dermatology of Saint Louis University, St. Louis, Mo. and a RAPTIVA clinical investigator. "RAPTIVA
'"/>

Contact: Emmy Tsui
emmy.tsui@ketchum.com
585-256-0195
Ketchum
27-Oct-2003


Page: 1 2 3 4 5 6

Related biology news :

1. FDA approves VYTORIN, first and only to powerfully reduce LDL cholesterol through dual inhibition
2. European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer
3. FDA approves Abbotts Biaxin XL (clarithromycin extended-release tablet)for community-acquired pneumonia
4. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia
5. DFG approves 14 new research training units
6. National Science Board approves five new NSF Science and Technology Centers
7. Phase III study results with Raptiva in the treatment of psoriasis presented at Annual AAD meeting
8. Results from open-label Raptiva study suggest continued benefit with long-term treatment
9. Genes appear to play a role in development of chronic obstructive pulmonary disease
10. New research supports theory that indirect transmission of chronic wasting disease
11. Animal studies show promise treating severe chronic pain

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... ... ... Exalto Bearings UK, the manufacturer of high quality rubber-lined cutlass ... Business Manager. , Cosgrove has over 30 years of experience within the engineering and ... Derby UK facility. , “We are pleased to have Mike join our team,” said ...
(Date:10/11/2018)... , ... October 11, 2018 , ... ... the vision behind the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The ... projects designed to advance biopharmaceutical manufacturing and workforce development in the United States. ...
(Date:10/5/2018)... ... October 04, 2018 , ... EDETEK, the premier provider of digital ... U.S. Interchange in Bethesda, MD on October 8-12, 2018. EDETEK is also a Gold ... November 5-6, 2018. , CDISC Interchanges are global events held annually on three ...
Breaking Biology News(10 mins):
(Date:10/16/2018)... Bethesda, MD (PRWEB) , ... October 15, 2018 , ... ... and Leadership Award recipients. The leaders will receive their awards at the AMIA ... , The symposium draws more than 2,500 attendees. This year garnered more than 700 ...
(Date:10/11/2018)... , ... October 11, 2018 , ... ... label printing and software solutions, in collaboration with HP, the global leader in ... Avery UltraDuty GHS Chemical Labels on all HP PageWide Printers. , The award-winning ...
(Date:10/5/2018)... Pa. (PRWEB) , ... October 04, 2018 , ... ... a new brand identity and website that elevates the company’s brand identity and ... EARTHRES, the company offers a broader range of engineering expertise and related support ...
(Date:10/2/2018)... ... October 02, 2018 , ... ... endangers the reliability and reproducibility of experimental data. Each lab must consider whether ... educational webinar, which is sponsored by Eppendorf , attendees will learn how ...
Breaking Biology Technology:
Cached News: